Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Pharmacol. 2015 Oct;24:7-11. doi: 10.1016/j.coph.2015.06.003. Epub 2015 Jun 25.

The global challenge of new classes of antibacterial agents: an industry perspective.

Author information

1
Cempra, Inc., Building Two, 6320 Quadrangle Drive, Suite 360, Chapel Hill, NC 27517, USA. Electronic address: prabha@fernandes-domain.com.

Abstract

With rising antibiotic resistance and the fear of returning to the pre-penicillin era, incentives are being provided for developing novel antibiotics. The hurdles faced by antibiotic developers include the difficulty in discovering novel chemicals that have selectivity and the increased regulatory scrutiny for safety and efficacy. Furthermore, the demonstration of superiority is essential in order to rationalize pricing and to assure a return on investment. Suggestions are provided to overcome each of these hurdles in order to prevent the antibiotic pipeline from running dry.

PMID:
26119487
DOI:
10.1016/j.coph.2015.06.003
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center